Logo image
Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints
Journal article   Open access   Peer reviewed

Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints

Amey Holmes, Lawrence J Coppey, Eric P Davidson and Mark A Yorek
Journal of diabetes research, Vol.2015, pp.307285-8
2015
DOI: 10.1155/2015/307285
PMCID: PMC4503545
PMID: 26229968
url
https://doi.org/10.1155/2015/307285View
Published (Version of record) Open Access

Abstract

We examined whether reversal of high fat diet, stimulating weight loss, compared to two treatments previously shown to have beneficial effects, could improve glucose utilization and peripheral neuropathy in animal models of obesity and type 2 diabetes. Rats were fed a high fat diet and treated with a low dose of streptozotocin to create models of diet induced obesity or type 2 diabetes, respectively. Afterwards, rats were transferred to a normal diet or treated with enalapril or dietary enrichment with menhaden oil for 12 weeks. Obesity and to a greater extent type 2 diabetes were associated with impaired glucose utilization and peripheral neuropathy. Placing obese rats on a normal diet improved glucose utilization. Steatosis but not peripheral neuropathy was improved after placing obese or diabetic rats on a normal diet. Treating obese and diabetic rats with enalapril or a menhaden oil enriched diet generally improved peripheral neuropathy endpoints. In summary, dietary improvement with weight loss in obese or type 2 diabetic rats was not sufficient to correct peripheral neuropathy. These results further stress the need for discovery of a comprehensive treatment for peripheral neuropathy.
Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Anti-Obesity Agents - therapeutic use Biomarkers - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diet therapy Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - etiology Diabetic Neuropathies - complications Diabetic Neuropathies - prevention & control Diet, Fat-Restricted Diet, High-Fat - adverse effects Dietary Supplements Disease Models, Animal Enalapril - therapeutic use Fish Oils - therapeutic use Hypoglycemic Agents - therapeutic use Male Neuralgia - complications Neuralgia - prevention & control Non-alcoholic Fatty Liver Disease - complications Obesity - complications Obesity - diet therapy Obesity - drug therapy Obesity - etiology Rats, Sprague-Dawley Streptozocin - toxicity Weight Loss - drug effects

Details

Metrics

Logo image